🧬 Through the MEUSIX project with @biomarinpharma.bsky.social and @ec.europa.eu funding, we launched the first AAV-based gene therapy trial for MPS VI — showing promising safety and efficacy. Why gene therapy?
Because current treatments fall short. We aim for a one-time, lasting solution.
Because current treatments fall short. We aim for a one-time, lasting solution.
May 15, 2025 at 4:38 PM
🧬 Through the MEUSIX project with @biomarinpharma.bsky.social and @ec.europa.eu funding, we launched the first AAV-based gene therapy trial for MPS VI — showing promising safety and efficacy. Why gene therapy?
Because current treatments fall short. We aim for a one-time, lasting solution.
Because current treatments fall short. We aim for a one-time, lasting solution.